Advanced Filters
noise

Eye Disease Clinical Trials

A listing of Eye Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 326 clinical trials

Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD). The main questions it aims to answer are: Safety and tolerability of the novel stem cell formulation Potential efficacy …

50 - 100 years of age All Phase 1/2
J Jiaxu Hong

JN002 for the Treatment of Dry Eye Disease

This is a first-in-human, single-center, randomized, double-blind, placebo-controlled clinical trial designed to:·Evaluate the efficacy of JN002 Ophthalmic Solution in treating dry eye disease (DED)·Assess the safety of JN002 Ophthalmic SolutionResearchers will compare three groups-placebo (vehicle), low-dose JN002 (0.05 mg/mL), and high-dose JN002 (0.1 mg/mL)-to evaluate whether JN002 Ophthalmic Solution improves …

18 years of age All Phase 0
E Eyvind Rødahl, MD PhD

Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease

The purpose of this study is to determine whether Sirolimus is more effective and burdened with less side effects than conventional treatment with corticosteroids in patients with active thyroid eye disease.

18 - 80 years of age All Phase 2

Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease

Objective: To evaluate the effect of transcutaneous auricular vagus nerve stimulation (taVNS) for the patients with dry eye disease with meibomian gland dysfunction. Methods: We enrolled 256 patients at Beijing Tongren Hospital. Patients completed questionnaires at baseline, 1 month, 3 months, and 6 months.OSDI score, TBUT, Schirmer I, tCFS, MGD …

18 - 65 years of age All Phase 2

Evaluation of BTV100 in Subjects With Dry Eye Disease

This study will be a randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study to evaluate the efficacy, safety and tolerability of repeat dosing of Cevimeline Ophthalmic Solution compared to the vehicle in subjects with Dry Eye Disease (DED).

18 years of age All Phase 2
E Ethics Committee

MHB018A Treatment in Patients With Active Thyroid Eye Disease

The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.

18 - 75 years of age All Phase 3
E Eve Adcock, CCRC

SGLT2 Inhibitors in Geographic Atrophy

AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and …

50 years of age All Phase 2
C Connie Dampier

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be …

18 - 75 years of age All Phase 1
C Chadwick Prodromos, M.D.

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases

This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Eye diseases

years of age All Phase 1
h huifang zhou, Doctor

A Study of GenSci098 in Subjects With Active Thyroid Eye Disease

To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)

18 - 75 years of age All Phase 1

Simplify language using AI